

11/27/01
JCS 885 U.S. PTO


11-30-01

Customer No. 000959
Case Docket No. PPI-105

④

Commissioner for Patents
BOX PATENT APPLICATION
U.S. Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

11046 U.S. PTO
09/996357
11/27/01

"Express Mail" Mailing Label Number	EL 833 312 780 US
Date of Deposit	November 27, 2001
<p>I hereby certify that this transmittal letter and the papers referred to as being enclosed therein are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents, BOX PATENT APPLICATION, U.S. Patent and Trademark Office, P.O. Box 2327, Arlington, VA 22202</p> <p> Signature</p> <p>Ilidio P. Cardoso Please Print Name of Person Signing</p>	

Dear Sir:

Transmitted herewith for filing is the Utility patent application of:

Inventor(s): Malcolm L. Gefter; David I. Israel; John L. Joyal; and Michael Gosselin

For: *"Therapeutic Agents and Methods of Use Thereof For Treating an Amyloidogenic Disease"*

Enclosed are:

- 51 pages of Specification, 9 pages of Claims and 1 page of Abstract;
- 12 sheets of Drawings (Figures 1- 12);
- 5 pages of *unexecuted* Declaration, Petition and Power of Attorney;
- Transmittal Letter for Diskette Containing Sequence Listing;
- 6 pages of Sequence Listing (Paper Copy);
- Diskette Containing Computer Readable Copy of the Sequence Listing;
- 4 pages of Application Data Sheet;
- 1 page of Statement of Limited Recognition Under 37 C.F.R. §10.9(b) for Maria C. Laccotripe; and
- Pre-paid Acknowledgment Postcard.
- Applicant claims small entity status. See 37 C.F.R. 1.27.

The filing fee has been calculated as shown below:

(Col. 1)	(Col. 2)	
FOR:	NO. FILED	NO. EXTRA
BASIC FEE	//////////	
TOTAL CLAIMS	183 - 20	= 163
INDEP. CLAIMS	4 - 3	= 1
<input checked="" type="checkbox"/> MULTIPLE DEPENDENT CLAIMS PRESENTED		

* If the difference in Col. 2 is less than zero,
enter "0" in Col. 2.

SMALL ENTITY	
RATE	FEES
//////////	\$ 370
OR	
x 9=	\$ 1467
OR	
x 42	\$ 42
OR	
+140	\$ 140
TOTAL	\$2019.00

OTHER THAN SMALL ENTITY	
RATE	FEES
//////////	\$
OR	
x 18=	\$
OR	
x 84	\$
OR	
+280	\$
OR	
TOTAL	0

FILING FEES ARE NOT BEING PAID AT THIS TIME.

The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. _____.

Any additional filing fees required under 37 C.F.R. 1.16.

Any patent application processing fees under 37 C.F.R. 1.17.

The Commissioner is hereby authorized to charge payment of the following fees during the pendency of this application or credit any overpayment to Deposit Account No. _____.

Any patent application processing fees under 37 C.F.R. 1.17.

The issue fee set in 37 C.F.R. 1.18 at or before mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b).

Any filing fees under 37 C.F.R. 1.16 for presentation of extra claims.

Address all future communications to **Giulio A. DeConti, Jr., Esq.** at Customer No. 000959 whose address is:

Lahive & Cockfield, LLP
28 State Street
Boston, Massachusetts 02109

Date: November 27, 2001

LAHIVE & COCKFIELD, LLP
Attorneys at Law

By: *[Signature]*
Maria C. Laccotripe, Ph.D., J.D.
Limited Recognition Under 37 C
Agent for Applicant
28 State Street
Boston, MA 02109
Telephone (617) 227-7400
Facsimile (617) 742-4214

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Malcolm L. Gefter, *et al.*

Serial No.: filed herewith

Filed: November 27, 2001

For: THERAPEUTIC AGENTS AND METHODS
OF USE THEREOF FOR TREATING AN
AMYLOIDOGENIC DISEASE

Attorney Docket No.: PPI-105

Group Art Unit: unknown

Examiner: unknown

Commissioner for Patents
Box Sequence
Washington, D.C. 20231

TRANSMITTAL LETTER FOR DISKETTE CONTAINING SEQUENCE LISTING

Dear Sir:

Enclosed is a diskette which contains a computer readable form of the Sequence Listing for the above-referenced patent application. The Sequence Listing complies with the requirements of 37 C.F.R. § 1.821. The material on this diskette is identical in substance to the sequence listing appearing on pages 1- 6 of the Sequence Listing which is submitted herewith, as required by 37 C.F.R. § 1.821(f). The computer readable form of the sequence listing contained on the enclosed diskette is understood to comply with the requirements of § 1.824(d).

"Express Mail" Mailing Label Number EL 833 312 780 US

Date of Deposit November 27, 2001

I hereby certify that this transmittal letter and the papers referred to as being enclosed therein are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents, BOX PATENT APPLICATION, U.S. Patent and Trademark Office, P.O. Box 2327, Arlington, VA 22202




Signature

Ilidio P. Cardoso

Please Print Name of Person Signing

Respectfully submitted,



Maria C. Laccotripe, Ph.D., J.D.
Limited Recognition Under 37 C.F.R. §10.9(b)
Agent for Applicant
LAHIVE & COCKFIELD, LLP
28 State Street
Boston, MA 02109
(617) 227-7400

Date: November 27, 2001

**BEFORE THE OFFICE OF ENROLLMENT AND DISCIPLINE
UNITED STATE PATENT AND TRADEMARK OFFICE**

LIMITED RECOGNITION UNDER 37 CFR § 10.9(b)

Maria C. Laccotripe is hereby given limited recognition under 37 CFR §10.9(b) as an employee of Lahive & Cockfield, LLP, to prepare and prosecute patent applications where the patent applicant is the client of Lahive & Cockfield, LLP, and the attorney or agent of record in the applications is a registered practitioner who is a member of the Lahive & Cockfield, LLP. This limited recognition shall expire on the date appearing below, or when whichever of the following events first occurs prior to the date appearing below: (i) Maria C. Laccotripe ceases to lawfully reside in the United States, (ii) Maria C. Laccotripe's employment with Lahive & Cockfield, LLP ceases or is terminated, or (iii) Maria C. Laccotripe ceases to remain or reside in the United States on an H-1 visa.

This document constitutes proof of such recognition. The original of this document is on file in the Office of Enrollment and Discipline of the U.S. Patent and Trademark Office.

Expires: September 4, 2002



Harry L. Moatz
Director of Enrollment and Discipline